Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting.
Moloney B, Li X, Hirano M, Saad Eddin A, Lim JY, Biswas D, Kazerouni AS, Tudorica A, Li I, Bryant ML, Wille C, Pyle C, Rahbar H, Hsieh SK, Rice-Stitt TL, Dintzis SM, Bashir A, Hobbs E, Zimmer A, Specht JM, Phadke S, Fleege N, Holmes JH, Partridge SC, Huang W. Moloney B, et al. Among authors: specht jm. Front Oncol. 2024 Nov 29;14:1395502. doi: 10.3389/fonc.2024.1395502. eCollection 2024. Front Oncol. 2024. PMID: 39678499 Free PMC article.
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA. Partridge SC, et al. Among authors: specht jm. J Magn Reson Imaging. 2010 Nov;32(5):1124-31. doi: 10.1002/jmri.22362. J Magn Reson Imaging. 2010. PMID: 21031518 Free PMC article.
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Dunnwald LK, et al. Among authors: specht jm. J Clin Oncol. 2008 Sep 20;26(27):4449-57. doi: 10.1200/JCO.2007.15.4385. Epub 2008 Jul 14. J Clin Oncol. 2008. PMID: 18626006 Free PMC article.
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.
Chau B, Loggers ET, Cranmer LD, Mogal H, Sharib JM, Kim EY, Schaub SK, Paulson KG, Linden HM, Specht JM, Kim JN, Javid SH, Wagner MJ. Chau B, et al. Among authors: specht jm. Am J Clin Oncol. 2023 Dec 1;46(12):567-571. doi: 10.1097/COC.0000000000001045. Epub 2023 Sep 19. Am J Clin Oncol. 2023. PMID: 37725702 Free PMC article.
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Connolly RM, et al. J Clin Oncol. 2019 Mar 20;37(9):714-722. doi: 10.1200/JCO.2018.78.7986. Epub 2019 Feb 5. J Clin Oncol. 2019. Retraction in: J Clin Oncol. 2021 Jul 10;39(20):2319. doi: 10.1200/JCO.21.00752 PMID: 30721110 Free PMC article. Retracted. Clinical Trial.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Layman RM, et al. Among authors: specht jm. Lancet Oncol. 2024 Apr;25(4):474-487. doi: 10.1016/S1470-2045(24)00034-2. Lancet Oncol. 2024. PMID: 38547892 Clinical Trial.
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Connolly RM, et al. J Clin Oncol. 2021 Jul 10;39(20):2247-2256. doi: 10.1200/JCO.21.00280. Epub 2021 May 17. J Clin Oncol. 2021. PMID: 33999652 Free PMC article. Clinical Trial.
65 results